Baltimore medical device startup ReGelTec is conducting a trial on patients and reporting new $3.75 million in funding as it develops a treatment for chronic low back pain. As with any medical ...

BALTIMORE--(BUSINESS WIRE)--ReGelTec Inc., a company developing a percutaneous hydrogel implant for the treatment of chronic low back pain caused by degenerative disc disease, announced it has ...

After leading Harpoon Medical to a $100 million acquisition by Edwards Lifesciences last year, CEO Bill Niland and three other executives are now working on a fledgling medial device startup creating ...

BALTIMORE, June 18, 2025--(BUSINESS WIRE)--ReGelTec Inc., a company developing a percutaneous hydrogel implant for the treatment of chronic low back pain caused by degenerative disc disease, announced ...

ReGelTec has secured CE Mark approval for the Class III Hydrafil System for disc augmentation, under the European Union Medical Device Regulation (MDR). The approval is based on a clinical trial ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. ReGelTec will use the new funding to expand an ongoing ...

BALTIMORE--(BUSINESS WIRE)--ReGelTec, Inc., a medical device company developing a percutaneous treatment for chronic low back pain, announced today that it has received Breakthrough Device designation ...

Please provide your email address to receive an email when new articles are posted on . ReGelTec Inc. announced it has received breakthrough device designation from the FDA for its Hydrafil system for ...

Clinical data show the percutaneous disc augmentation system generated significant improvements in pain and disability scores through 2-year follow-up CE Mark approval for the HYDRAFIL System was ...